Sharon Stoll, DO
Neurology · New Haven, CTNPI 1114211174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $558,190 of the $822,228 with a category attached, or 67.9%. 24 manufacturers reported payments, led by Biogen at 35.3% of the total. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 967 payments — averaging $850.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$290K
- Sanofi$128K
- AstraZeneca$99K
- EMD Serono, Inc.$83K
- Novartis$46K
- TG Therapeutics, Inc.$39K
- plus $138K from 18 others
Across 13 payments — averaging $2478.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$25K
- F. Hoffmann-la Roche AG$5K
- Genentech, Inc.$2K
What the payments were for
- Consulting fees$163,58420%
- Speaking & faculty fees$558,19068%
- Travel & lodging$73,6909%
- Food & beverage$26,4983%
- Education$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 259 | $290,257 |
| Sanofi | 109 | $127,803 |
| AstraZeneca | 98 | $99,097 |
| EMD Serono, Inc. | 92 | $83,173 |
| Novartis | 116 | $45,716 |
| TG Therapeutics, Inc. | 37 | $38,540 |
| Amgen(2 entities) | 40 | $38,107 |
| E.r. Squibb & Sons, L.L.C. | 23 | $25,593 |
| Genentech USA, Inc. | 41 | $18,236 |
| Sanofi US Services Inc. | 1 | $16,212 |
| Genentech, Inc. | 27 | $11,543 |
| Bristol Myers Squibb | 54 | $9,888 |
| Roche Products Limited | 9 | $9,077 |
| Novartis Pharma AG | 2 | $7,700 |
| AbbVie | 24 | $298 |
| Sanofi-aventis U.S. LLC | 5 | $285 |
| Eisai Inc. | 3 | $178 |
| Pfizer | 14 | $158 |
| Axsome Therapeutics, Inc. | 4 | $154 |
| Inspire Medical Systems, Inc. | 2 | $74 |
| Lilly USA, LLC | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$822,228 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in New Haven
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
- Marcelo MatielloNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.